Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Big R&D Investment Trend as Mid-Cap Biotechs Push to Get Drugs to Market

Published: Thursday, March 07, 2013
Last Updated: Thursday, March 07, 2013
Bookmark and Share
20% of overall increase in R&D expenditure in just a year.

Biotech firms eager to push drug candidates through clinical trials prompted an overall increase in R&D expenditure of 20% in just a year, states research and consulting firm GlobalData.

GlobalData’s new report, which compares the competitive position of 15 innovative mid-cap biotech companies on 20 financial metrics, states that the peer group R&D spend for Q3 2012 reached US$746.8m, climbing from US$621.1m in Q3 2011.

“Oncology is the main focus of biotech R&D activities,” says Adam Dion, GlobalData’s Analyst covering Healthcare Industry Dynamics, “which is driving peer group R&D expenses higher.”

Regeneron was the firm with the highest R&D expenditure for Q3 2012, with an outlay of US$158m.

According to the report, Regeneron’s R&D spend has increased steadily each quarter since Q3 2011, when the total stood at US$128m.

“Biotech companies are becoming increasingly more successful at developing innovative therapies,” says Dion. “However, our research has found that the high cost of bringing these therapies to market continues to erode corporate profitability.”

In terms of percentages, ViroPharma displayed the biggest year-to-year drop in R&D expenditure.

The company’s R&D spending plummeted 28% year-to-year, from US$22.9m in Q3 2011 to US$16.5m in Q3 2012.

The decrease in ViroPharma’s R&D spend was caused by the Food and Drug Administration’s suspension of the company’s clinical trials of its flagship product Cinryze due to safety concerns.

“The FDA put a hold on two of the company’s Phase II clinical studies when trials revealed elevated antibody levels detected in the treatment arm of the study,” explains Dion. “These concerns have since been addressed and, with FDA approval, the firm resumed the trials in September of last year.”

As defined by a proprietary ratings system based on a number of financial metrics including revenue, sales growth and cost containment, GlobalData identified Regeneron as the peer group benchmark leader in the third quarter, overtaking the Q2 2012 number one, Alexion.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

The Fall from Grace of Peregrine Pharmaceuticals
On September 24, 2012, the company announced the discovery of ‘major data discrepancies’ between reported results and patient treatment code assignments.
Wednesday, October 17, 2012
T-DM1 Demonstrates Overall Survival Benefit in Metastatic Breast Cancer
Next target, FDA approval.
Thursday, August 30, 2012
Tofacitinib: Sacrificing Safety for Novelty?
FDA has extended the review period of tofacitinib by three months.
Wednesday, August 22, 2012
Poor Healthcare Policies and Infrastructure, But India’s Pharma Market Continues to Boom
Country’s pharmaceutical industry continue to expand rapidly in the coming years.
Tuesday, August 21, 2012
Aplastic Anemia Patients in Need of New Treatment Options
New study explores the failings of current treatment options for aplastic anemia.
Friday, February 24, 2012
Scientific News
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Computerized Flexible Needles Prove Themselves in Biological Tissue
The advantage of the system is that you can avoid obstacles with the needles or critical tissues and that the system during the insertion of the needle in real time can adjust the path if, for example, the tissue deforms.
DARWIN 2 24-week Monotherapy Data in RA Confirm Previous Results
Safety profile in DARWIN 2 consistent with previous filgotinib RA studies.
Researchers Publish Landmark “Basket Study”
Researchers from Memorial Sloan Kettering Cancer Center (MSK) have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients’ tumors rather than where their cancer originated.
Agricultural Intervention Improves HIV Outcomes
A multifaceted farming intervention can reduce food insecurity while improving HIV outcomes in patients in Kenya, according to a randomized, controlled trial led by researchers at UC San Francisco.
Overdose of Vitamin D in Teenagers May Lead to Increased Cholesterol Levels
Dosing obese teens with vitamin D shows no benefits for their heart health or diabetes risk, and could have the unintended consequences of increasing cholesterol and fat-storing triglycerides. These are the latest findings in a series of Mayo Clinic studies in childhood obesity.
Phase 2 Trials Underway for New Single Dose Malaria Treatment
The new drug, which prevents the malaria parasite from reproducing and spreading, is now undergoing Phase II clinical trials in humans.
Promising Drug for Parkinson's Disease
A drug which has already been in use for decades to treat liver disease could be an effective treatment to slow down progression of Parkinson’s disease, scientists from the University of Sheffield have discovered.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!